These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21209033)

  • 1. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.
    Hegedüs L; Moses AC; Zdravkovic M; Le Thi T; Daniels GH
    J Clin Endocrinol Metab; 2011 Mar; 96(3):853-60. PubMed ID: 21209033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
    Bjerre Knudsen L; Madsen LW; Andersen S; Almholt K; de Boer AS; Drucker DJ; Gotfredsen C; Egerod FL; Hegelund AC; Jacobsen H; Jacobsen SD; Moses AC; Mølck AM; Nielsen HS; Nowak J; Solberg H; Thi TD; Zdravkovic M; Moerch U
    Endocrinology; 2010 Apr; 151(4):1473-86. PubMed ID: 20203154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 receptor agonist-induced polyarthritis: a case report.
    Ambrosio ML; Monami M; Sati L; Marchionni N; Di Bari M; Mannucci E
    Acta Diabetol; 2014 Aug; 51(4):673-4. PubMed ID: 24158775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide (Victoza) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys.
    Vahle JL; Byrd RA; Blackbourne JL; Martin JA; Sorden SD; Ryan T; Pienkowski T; Wijsman JA; Smith HW; Rosol TJ
    Endocrinology; 2015 Jul; 156(7):2409-16. PubMed ID: 25860028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
    Lorber D
    Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid safety in patients treated with liraglutide.
    Gallo M
    J Endocrinol Invest; 2013 Feb; 36(2):140-5. PubMed ID: 23481614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice.
    Rosol TJ
    Toxicol Pathol; 2013 Feb; 41(2):303-9. PubMed ID: 23471186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.